![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Mtbvac, the spanish tuberculosis vaccine, the first live attenuated vaccine of Mycobacterium tuberculosis, which is under clinical development for the treatment of tuberculosis in adults.
Lead Product(s): Mtbvac
Therapeutic Area: Infections and Infectious Diseases Product Name: Mtbvac
Highest Development Status: Phase IIIProduct Type: Vaccine
Recipient: Bharat Biotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2024
Details:
Under the agreement, IAVI is supporting development, global regulatory strategy, resource mobilization, and access planning for the adolescent/adult tuberculosis (TB) vaccine candidate MTBVAC.
Lead Product(s): MTBVAC
Therapeutic Area: Infections and Infectious Diseases Product Name: MTBVAC
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: IAVI
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 17, 2023
Details:
This agreement between BHARAT BIOTECH and BIOFABRI would guarantee the worldwide production and the supply of the future vaccine, MTBVAC in more than 70 countries with a high TB incidence, such as India, country with the highest TB burden in the world, with a 25% of all cases.
Lead Product(s): MTBVAC,BCG Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: MTBVAC
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Bharat Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 16, 2022